Project Grant R01DK144402
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $512,595 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 15, 2026 through February 28, 2030. This research award supports basic biomedical research investigating novel neural circuits controlling urinary and fecal continence through the mapping...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $751,694 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 21, 2026, through February 28, 2031. The award funds preclinical research to optimize tibial nerve stimulation (TNS) therapy for treating neurogenic bladder dysfunction in individuals with...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded University of California, Irvine $350,902 on July 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support an investigator-initiated research project examining urethral dysfunction in female urinary incontinence. The project, which runs through March 31, 2030, will deliver comprehensive research services focused on unraveling...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Medical College of Wisconsin, Inc. a Project Grant of $432,625 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop animal models and resources for preclinical lower urinary tract research. The award, effective August 6, 2025, through July 31, 2027, supports the creation of a comprehensive dataset measuring urological...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $765,701 Project Grant award dated September 9, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds basic biomedical research to map mechanosensory neural circuits controlling bladder sensation and urination through the completion date of May 31, 2030. The research will employ...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $177,350 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2030. The project develops objective analytical tools and predictive methodologies to advance sacral neuromodulation (SNM) treatment optimization for overactive bladder...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the Regents of the University of Michigan a $390,000 Project Grant effective September 5, 2025, through June 30, 2030, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research initiative investigates the consequences of step therapy—an insurance utilization management strategy requiring documented treatment failures before...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Nevada, Reno a $2.56 million Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective September 15, 2025, with a completion date of September 14, 2029. This research award funds a four-year investigative project examining novel regulatory targets for gastrointestinal hormones and neuropeptides in...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $796,742 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 6, 2026, through December 31, 2029. The award funds development and validation of urinary peptide biomarkers for risk stratification in patients with spina bifida-related...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Southern California a $807,860 Project Grant on September 12, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct the SUSTAIN (Stroke Volume-Based Fluid Resuscitation in Acute Pancreatitis) multi-center randomized controlled trial. The three-year award, with completion scheduled for September 11, 2028,...
Grant Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Rancho Research Institute (doing business as LOS Amigos Research & ED Institute) a Project Grant of $727,810 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective June 1, 2026 through March 31, 2031. This research initiative investigates functional and structural brain connectivity alterations in post-stroke lower urinary tract dysfunction, addressing a significant clinical gap in treating urinary incontinence affecting approximately 30% of stroke survivors. The project delivers three integrated research aims utilizing advanced neuroimaging and clinical intervention methodologies. The grant funds comprehensive research services including task-based and resting-state functional magnetic resonance imaging (fMRI) analysis to map connectivity disruptions among bladder-control brain hubs (Aim 1); diffusion-MRI tractography to characterize white-matter pathway injuries mediating functional disconnection (Aim 2); and clinical delivery of a 12-week transcutaneous spinal cord stimulation (TSCS) intervention paired with outcome assessment to establish prospectively validated biomarker panels predicting treatment response (Aim 3). Collectively, these research activities are designed to identify neurobiological predictors of treatment success for a non-invasive neuromodulation therapy, ultimately enabling clinician-guided patient selection and improving quality of life for stroke survivors with chronic lower urinary tract dysfunction.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $727.8k | 6/1/26 |